PE
REGN icon

PCM Encore’s Regeneron Pharmaceuticals REGN Stock Holding History

PCM Encore’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$625K Sell
1,003
-48
-5% -$32.7K 0.11% 171
2026
Q1 		$812K Buy
1,051
+41
+4% +$31.4K 0.17% 119
2025
Q4 		$780K Buy
+1,010
New +$686K 0.17% 118

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

PCM Encore's REGN Position: Q2 2026 in Review

PCM Encore reduced its Regeneron Pharmaceuticals (REGN) stake by 4.6% in Q2 2026, selling an estimated $32.7K and leaving 1,003 shares worth $625K. The position accounts for 0.11% of the portfolio, ranked #171.

PCM Encore first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $812K in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • PCM Encore held 1,003 shares of Regeneron Pharmaceuticals worth $625K as of Q2 2026.
  • PCM Encore sold 48 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $32.7K.
  • Regeneron Pharmaceuticals made up 0.11% of PCM Encore's portfolio in Q2 2026, its #171 holding.
  • PCM Encore first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PCM Encore's Regeneron Pharmaceuticals position peaked at $812K in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on PCM Encore's 13F filing for Q2 2026, filed 11 Aug 2026.